Center-Authored Papers

Filters: Author is Gerbing, Robert B  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
Woods WG, Franklin ARK, Alonzo TA, Gerbing RB, Donohue KA, Othus M, Horan J, Appelbaum FR, Estey EH, Bloomfield CD et al..  2013.  Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.. Cancer. Abstract
Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA et al..  2010.  High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(17):2831-8. Abstract
Walter RB, Laszlo GS, Alonzo TA, Gerbing RB, Levy S, Fitzgibbon MP, Gudgeon CJ, Ries RE, Harrington KH, Raimondi SC et al..  2013.  Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: A report from the children's oncology group.. American journal of hematology. 88(8):694-702. Abstract
V
Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Wang Y-C, Gerbing RB, Sung L et al..  2017.  Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.. Blood. Abstract
Vujkovic M, Attiyeh EF, Ries RE, Horn M, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Gerbing RB, Hirsch B et al..  2015.  Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group.. Cancer genetics. Abstract
T
Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS et al..  2014.  Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.. British journal of haematology. Abstract
Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi S, Hirsch BA, Kahwash SB et al..  2017.  Disease Characteristics and Prognostic Implications of Cell Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
S
Sung L, Aplenc R, Alonzo TA, Gerbing RB, Wang Y-C, Meshinchi S, Gamis AS.  2016.  Association between Prolonged Neutropenia and Reduced Relapse Risk in Pediatric AML: A Report from the Children's Oncology Group.. International journal of cancer. Abstract
R
Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ, Meshinchi S.  2012.  FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.. Blood. Abstract
Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang Y-C, Loken MR, Raimondi SC, Hirsch BA, Gamis AS et al..  2016.  miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.. Pediatric blood & cancer. Abstract
P
Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB et al..  2012.  Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.. Blood. 119(16):3705-11. Abstract
Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S.  2016.  CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M et al..  2010.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.. Blood. 115(12):2372-9. Abstract
O
Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR et al..  2014.  NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.. Blood. 124(15):2400-7. Abstract
M
Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J et al..  2013.  Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(6):1620-1627. Abstract
Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S.  2013.  BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract
Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland GD, Radich JP.  2008.  Structural and numerical variation of FLT3/ITD in pediatric AML.. Blood. 111(10):4930-3. Abstract
Maxson JE, Ries RE, Wang Y-C, Gerbing RB, Kolb AE, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y, Zong Z et al..  2016.  CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.. Blood. 127(24):3094-3098.
L
Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS et al..  2012.  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.. Blood. Abstract
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang Y-C, Ries RE, Raimondi SC, Hirsch BA et al..  2015.  High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Journal of hematology & oncology. 8(1):115. Abstract
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang Y-C, Ries RE, Raimondi SC, Hirsch BA et al..  2016.  Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Journal of hematology & oncology. 9(1):133.
Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S et al..  2014.  High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Leukemia & lymphoma. 55(12):2817-21. Abstract
K
Kutny MA, Alonzo TA, Gerbing RB, Wang Y-C, Raimondi SC, Hirsch BA, Fu CH, Meshinchi S, Gamis AS, Feusner JH et al..  2017.  Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016716183. Abstract
J
Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, Meshinchi S, Gamis AS.  2017.  Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract
H
Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, Becton D, Smith FO, Woods WG.  2008.  Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5797-801. Abstract